Literature DB >> 26019733

Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.

Jan Erik Slotta1, Otto Kollmar1, Volker Ellenrieder1, B Michael Ghadimi1, Kia Homayounfar1.   

Abstract

Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed.

Entities:  

Keywords:  Extended indications; Hepatocellular carcinoma; Interventional therapy; Multimodal treatment; Surgical therapy

Year:  2015        PMID: 26019733      PMCID: PMC4438492          DOI: 10.4254/wjh.v7.i9.1168

Source DB:  PubMed          Journal:  World J Hepatol


  159 in total

1.  Chemoembolization for intermediate HCC: is there proof of survival benefit?

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2011-10-17       Impact factor: 25.083

2.  Etiologic influence on chromosomal aberrations in European hepatocellular carcinoma identified by CGH.

Authors:  Kia Homayounfar; Alexandra Schwarz; Christina Enders; Silke Cameron; Daniel Baumhoer; Giuliano Ramadori; Thomas Lorf; Bastian Gunawan; Bjoern Sander
Journal:  Pathol Res Pract       Date:  2013-04-30       Impact factor: 3.250

3.  Histopathologic outcome of neoadjuvant image-guided therapy of hepatocellular carcinoma.

Authors:  Horia L Marin; E Elizabeth Furth; Kim Olthoff; Abraham Shaked; Michael C Soulen
Journal:  J Gastrointestin Liver Dis       Date:  2009-06       Impact factor: 2.008

4.  Three-dimensional conformal radiotherapy in combination with transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma.

Authors:  Wen-jun Chen; Shao-fei Yuan; Lin-jia Zhu; Xiao-nan Sun; Weie Zheng
Journal:  J BUON       Date:  2014 Jul-Sep       Impact factor: 2.533

5.  In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

Authors:  Amr El Fouly; Judith Ertle; Ahmed El Dorry; Mohamed K Shaker; Alexander Dechêne; Heba Abdella; Stefan Mueller; Eman Barakat; Thomas Lauenstein; Andreas Bockisch; Guido Gerken; Joerg F Schlaak
Journal:  Liver Int       Date:  2014-08-02       Impact factor: 5.828

Review 6.  Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma.

Authors:  Roberto S Oliveri; Jørn Wetterslev; Christian Gluud
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

7.  National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers.

Authors:  Catharine M Sturgeon; Michael J Duffy; Barry R Hofmann; Rolf Lamerz; Herbert A Fritsche; Katja Gaarenstroom; Johannes Bonfrer; Thorsten H Ecke; H Barton Grossman; Peter Hayes; Ralf-Thorsten Hoffmann; Seth P Lerner; Florian Löhe; Johanna Louhimo; Ihor Sawczuk; Kazuhisa Taketa; Eleftherios P Diamandis
Journal:  Clin Chem       Date:  2010-03-05       Impact factor: 8.327

Review 8.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

9.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

10.  Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization.

Authors:  Jian-Hong Zhong; Bang-De Xiang; Wen-Feng Gong; Yang Ke; Qin-Guo Mo; Liang Ma; Xing Liu; Le-Qun Li
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

View more
  19 in total

1.  Percutaneous radiofrequency ablation of hepatocellular carcinoma in cirrhosis: analysis of complications in a single centre over 20 years.

Authors:  Antonio Giorgio; Maria G Merola; Luca Montesarchio; Francesca Merola; Pietro Gatti; Carmine Coppola; Valentina Giorgio; Giorgio Calisti
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

2.  MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice.

Authors:  Heng Wu; Junyan Tao; Xiaolei Li; Tianpeng Zhang; Lei Zhao; Yao Wang; Lei Zhang; Jun Xiong; Zhi Zeng; Na Zhan; Clifford J Steer; Li Che; Mingjie Dong; Xiaomei Wang; Junqi Niu; Zhuoyu Li; Guiqing Yan; Xin Chen; Guisheng Song
Journal:  Hepatology       Date:  2017-10-30       Impact factor: 17.425

3.  Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma.

Authors:  Wei Wang; Wen Bin Liu; Da Bing Huang; Wei Jia; Chu Shu Ji; Bing Hu
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

4.  METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma.

Authors:  Jingyao Hu; Liang Yang; Xueqiang Peng; Minghuan Mao; Xiaodan Liu; Jianbo Song; Hangyu Li; Fu Chen
Journal:  Hum Cell       Date:  2022-09-10       Impact factor: 4.374

5.  DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation.

Authors:  Leonardo Lorente; Sergio T Rodriguez; Pablo Sanz; Agustín F González-Rivero; Antonia Pérez-Cejas; Javier Padilla; Dácil Díaz; Antonio González; María M Martín; Alejandro Jiménez; Purificación Cerro; Julián Portero; Manuel A Barrera
Journal:  World J Hepatol       Date:  2022-06-27

Review 6.  Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.

Authors:  Jian-Jun Gao; Zhen-Yan Shi; Ju-Feng Xia; Yoshinori Inagaki; Wei Tang
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

Review 7.  Hepatic resection beyond barcelona clinic liver cancer indication: When and how.

Authors:  Mattia Garancini; Enrico Pinotti; Stefano Nespoli; Fabrizio Romano; Luca Gianotti; Vittorio Giardini
Journal:  World J Hepatol       Date:  2016-04-18

8.  Which factors affect the long-term survival of patients with hepatocellular carcinoma UICC stage IV?

Authors:  A Bauschke; A Altendorf-Hofmann; C Malessa; S Schüle; J Zanow; U Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-15       Impact factor: 4.553

9.  Association between Pre-Transplant Serum Malondialdehyde Levels and Survival One Year after Liver Transplantation for Hepatocellular Carcinoma.

Authors:  Leonardo Lorente; Sergio T Rodriguez; Pablo Sanz; Pedro Abreu-González; Dácil Díaz; Antonia M Moreno; Elisa Borja; María M Martín; Alejandro Jiménez; Manuel A Barrera
Journal:  Int J Mol Sci       Date:  2016-04-05       Impact factor: 5.923

10.  Inhibition of Regulatory Volume Decrease Enhances the Cytocidal Effect of Hypotonic Shock in Hepatocellular Carcinoma.

Authors:  Michihiro Kudou; Atsushi Shiozaki; Toshiyuki Kosuga; Daisuke Ichikawa; Hirotaka Konishi; Ryo Morimura; Shuhei Komatsu; Hisashi Ikoma; Hitoshi Fujiwara; Kazuma Okamoto; Shigekuni Hosogi; Takashi Nakahari; Yoshinori Marunaka; Eigo Otsuji
Journal:  J Cancer       Date:  2016-07-08       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.